Deal combines Mindstrong’s digital phenotyping platform with Takeda’s development capabilities
|
PALO ALTO, Calif., Feb. 27, 2018 /PRNewswire/ -- Mindstrong Health, a startup transforming the diagnosis and treatment of neuropsychiatric disorders, has entered into a partnership with Takeda Pharmaceutical Company Limited (TSE: 4502) to explore the development of digital biomarkers for selected mental health conditions, in particular schizophrenia and treatment-resistant depression. "Takeda shares our goal of using innovative technology to gain insights that will improve outcomes for people living with mental health conditions," said Dr. Paul Dagum, Founder and CEO of Mindstrong Health. "We are pleased to partner with them to implement digital technology in the clinical development of novel assets and, hopefully, allow for faster delivery of meaningful therapies to patients." Mindstrong Health has developed digital biomarkers that continuously measure brain function from passively collected smartphone data. Takeda's technology, combined with the powerful Mindstrong Health platform will potentially enable the application of digital biomarkers to stratify mental health conditions and predict remission with novel therapeutic interventions. "Mental health disorders are complex, multifaceted conditions, and drug development in this area of unmet need is slow to progress," said Emiliangelo Ratti, Head, Neuroscience Therapeutic Area Unit at Takeda. "This partnership with Mindstrong Health exemplifies Takeda's motivation to engage in digital technologies to improve the clinical assessment of patients with mental health conditions who lack adequate treatment options." About Mindstrong Health Media Contacts: For Mindstrong:
View original content with multimedia:http://www.prnewswire.com/news-releases/mindstrong-health-and-takeda-partner-to-explore-development-of-digital-biomarkers-for-mental-health-conditions-300604553.html SOURCE Mindstrong Health |
Company Codes: Tokyo:4502, OTC-PINK:TKPYY |
